BioVersys AG | Finanzwire

Basculer en Français

9472	Companies
185370	Keywords
117721	Articles
99262	Press releases

Home
Companies
BioVersys AG

BRIEF

published on 08/29/2025 at 07:05, 3 months 7 days ago

BioVersys Schedules Release of Half-Year 2025 Financial Results

Conference Call Multidrug-resistant Bacteria BioVersys Financial Results Antibacterial Development Basel Biopharmaceutical
PRESS RELEASE

published on 08/29/2025 at 07:00, 3 months 7 days ago

Bioversys To announce its FIrst half 2025 financial results, Provide a business update And Host a Conference call
BioVersys AG to announce its Half-Year 2025 financial results, provide a business update, and host a conference call on September 10, 2025

Conference Call Half-year Results Financial Update BioVersys AG Antibacterial Products
BRIEF

published on 08/27/2025 at 07:05, 3 months 9 days ago

EMA Grants Orphan Designation to BioVersys for Tuberculosis Treatment

Drug Resistance BioVersys Tuberculosis Alpibectir EMA Orphan Designation
PRESS RELEASE

published on 08/27/2025 at 07:00, 3 months 9 days ago

BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis
BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis. The designation provides key incentives for addressing drug resistance in TB treatment

BioVersys Tuberculosis Alpibectir EMA Orphan Designation Ethionamide
BRIEF

published on 07/02/2025 at 07:05, 5 months 3 days ago

BioVersys and Shionogi Collaborate on NTM Clinical Candidate

Global Commercialization BioVersys Collaboration Shionogi Partnership NTM Clinical Candidate Ansamycin Platform
PRESS RELEASE

published on 07/02/2025 at 07:00, 5 months 3 days ago

BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE
BioVersys and Shionogi enter global research collaboration for NTM clinical candidate. BioVersys grants Shionogi license option for leads from BV500 program

Shionogi BioVersys Global Research Collaboration NTM Clinical Candidate
BRIEF

published on 06/30/2025 at 07:05, 5 months 5 days ago

BioVersys AG Annual General Meeting Yields Positive Outcomes

Financial Statements Strategic Initiatives Board Elections BioVersys AGM Capital Amendment
PRESS RELEASE

published on 06/30/2025 at 07:00, 5 months 5 days ago

BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
BioVersys AG announces results from its Annual General Meeting of Shareholders, including re-election of Board Members and amendment to capital range for strategic initiatives

Annual General Meeting Shareholders Board Members BioVersys AG Capital Range
BRIEF

published on 06/03/2025 at 07:05, 6 months 2 days ago

BioVersys Announces 2025 Annual General Meeting of Shareholders

Capital Increase Board Elections Shareholders Meeting 2025 AGM BioVersys AG
PRESS RELEASE

published on 06/03/2025 at 07:00, 6 months 2 days ago

BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025
BioVersys AG publishes Invitation to its Annual General Meeting of Shareholders 2025, including agenda with items such as annual report, elections, compensation approval, and capital range amendment

Annual General Meeting Shareholders Biopharmaceutical AGM 2025 BioVersys AG

Accesswire

Published on 12/05/2025 at 02:35, 5 hours 6 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 5 hours 11 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 41 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 36 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 41 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 41 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 11 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 50 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 16 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 26 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:00, 13 hours 41 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 56 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 57 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE